liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
Karolinska Institute.
Linköping University, Department of Medicine and Health Sciences, Clinical Pharmacology. Linköping University, Faculty of Health Sciences.
Karolinska Institute.
Uppsala University.
2011 (English)In: DRUG METABOLISM AND DISPOSITION, ISSN 0090-9556, Vol. 39, no 2, 247-255 p.Article in journal (Refereed) Published
Abstract [en]

The formulation vehicle Cremophor EL has previously been shown to affect paclitaxel kinetics, but it is not known whether it also affects the kinetics of paclitaxel metabolites. This information may be important for understanding paclitaxel metabolism in vivo and in the investigation of the role of genetic polymorphisms in the metabolizing enzymes CYP2C8 and CYP3A4/CYP3A5 and the ABCB1 transporter. In this study we used the population pharmacokinetic approach to explore the influence of predicted Cremophor EL concentrations on paclitaxel (Taxol) metabolites. In addition, correlations between genetic polymorphisms and enzyme activity with clearance of paclitaxel, its two primary metabolites, 6 alpha-hydroxypaclitaxel and p-3-hydroxypaclitaxel, and its secondary metabolite, 6 alpha-p-3-dihydroxypaclitaxel were investigated. Model building was based on 1156 samples from a study with 33 women undergoing paclitaxel treatment for gynecological cancer. Total concentrations of paclitaxel were fitted to a model described previously. One-compartment models characterized unbound metabolite concentrations. Total concentrations of 6 alpha-hydroxypaclitaxel and p-3-hydroxypaclitaxel were strongly dependent on predicted Cremophor EL concentrations, but this association was not found for 6 alpha-p-3-dihydroxypaclitaxel. Clearance of 6 alpha-hydroxypaclitaxel (fraction metabolized) was significantly correlated (p andlt; 0.05) to the ABCB1 allele G2677T/A. Individuals carrying the polymorphisms G/A (n = 3) or G/G (n = 5) showed a 30% increase, whereas individuals with polymorphism T/T (n = 8) showed a 27% decrease relative to those with the polymorphism G/T (n = 17). The correlation of G2677T/A with 6 alpha-hydroxypaclitaxel has not been described previously but supports other findings of the ABCB1 transporter playing a part in paclitaxel metabolism.

Place, publisher, year, edition, pages
American Soc. for Pharmacology andamp; Experimental Therapeutics , 2011. Vol. 39, no 2, 247-255 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-65564DOI: 10.1124/dmd.110.035394ISI: 000286317900012OAI: diva2:396789
Available from: 2011-02-11 Created: 2011-02-11 Last updated: 2011-02-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Green, Henrik
By organisation
Clinical PharmacologyFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 50 hits
ReferencesLink to record
Permanent link

Direct link